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INTRODUCTION
One of the innumerable prerequisites, and, at present,
most alarming to the author, for graduation from the University
of Nebraska College of Ivledicine is the writing of a Senior
Thesis; thus, the only ;lausible reason for this paper.
In considering irradiation therapy of bone neoplasms one
is first confronted with the problem of classification, which
will be the first division.

The etiology and incidence of bone

tumors as a whole is perhaps the second division.

The subject

matter then divides itself into the consideration of irradiation
therapy in each of the separate
(see page two).

headin~s

of the classification

Each in turn will be taken up as presented there.
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GL~SSIFIG~TION

of BONE NEOPLASMS

Before 1920, because of the rarity of bone neoplasms, few
men had observed enough cases to gather sufficient data to set
forth more than the crudest classification of this disease.
About the best they could do was to divide them into two main
groups, i.e., benign and malignant.
a Boston physician,

Co~~an,

However, at about this time

who was taking care of a patient

with a primary bone tumor became particularly interested in this
disease.

In order to gain more information, he wrote to numerous

friends asking them to send him their observations in similar cases.
This correspondence gradually became more extensive and eventually
evolved into the Registry of Bone Sarcoma.

Through the Registry

sufficient cases and data were collected to establish a more or
less satisfactory classification of bone tumors.

(34)

The classification as set forth by the Registry is as follows:
1.

Metastatic tumors primary in other tissues than bone.

2.

Periosteal fibrosarcoma •

. 3.

Osteogenic tumors, (a) benign, (b) malignant.

4.

Inflammatory conditions.

5.

Benign Giant Cell tumors.

6.

Angiomata, (a) benign, (b) malignant.

7.

Ewing's tumor.

8.

Myeloma.

The above classification has been used
Codman, Ewing,

Kolodn~y

by

such men as

and others who have made remarkable
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contributions towards the comprehension of this subject.

Of

course, these men do not agree in entirety with the above
classification.

However, to discuss, these conflicts would be

to diverge from the purpose of this paper.

I, therefore, refer

you to the well written papers presented by these authors.
(14, 35, 34, 52, and others).
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ETIOLOGY and INCIDENCE of BONE NEOPLASMS
Neoplastic lesions of bone are indeed quite rare.

Kolodney

(52) states that their occunrence is one in one thousand population.

In 123,285 hospital admittances, Moore (69) found 96

cases of primary bone tumors.

He reports, also, 277 cases of

metastatic malignancy occurring in 5, 883 cases of carcinoma.
Tumors of bone, as new-growths in other tissues still
baffle the man who attempts to explain their etiology.

Such

factors as age, sex, heredity, embryonic arrests, irritation or
trauma, constitutional predisposition and so forth, have all
been advanced but fail to withstand critical analysis.
Kolodney (52) emphasized trauma as frequently being linked
with primary bone neoplasms.

He brought out the fact that young

growing cells when they reach the stage of physiological maturity
cease to develop further.

This he terms "growth restraint.tt

However the mature cells do not lose their growth abilities,
the latter having merely changed from kinetic to potential.
Trauma with subsequent necessity for repair or regeneration
temporarily lifts this growth restraint.

He states that in some

instances, in the presence of predisposing factors which are
not understood, trauma may lead to a complete loss of growth
restraint in the traumatized region.

However, we must remember

that even though bone tumors frequently seemingly follow a history of trauma, trauma actually is rarely followed by a new
growth.
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METAST?'.TIC TUMORS of BONE; PRIMARY in
OTHER TISSUES THru~ BONE
The effect of irradiation upon metastatic lesions of bone
primary in other tissues was first demonstrated by Pfahler and
Parry (Rose, 83) in 1916.

At this time they reported a case

with bone destruction from metastatic carcinoma, which showed
regression of tumor, bene regeneration and a corresponding
clinical improvement following the use of radiation therapy.
This apparently introduced roentgen and radium rays as therapeutic measures in the treatment of secondary carcinoma of bone.
Since then)remarkable advance has been made as is evidenced by
the numerous studies of various authors now found in the
literature.
The site of the primary carcinoma is most frequently the
breast, then the prostate, and less commonly the lung, uterus
and cervix, thy-roid, urinary tract, and gastro-intestinal tract.
(63, 75, 42, 89).

Pfahler (75) and Herendeen (42) believe that

of all metastatic carcinoma to bone, which the radiologist is
called upon to treat, those of the breast are by far more
frequent.

Lenz and Freid (58) found in 165 cases of carcinoma

of the breast with metastases that in 85 cases (or 55 per cent)
the skeletal system was involved.

Leddy and Desjardins (56):

!tIn 573 inoperable cases of carcinoma of the breast, osseous
metastasis was second only to metastasis to the infraclavicular
node. It

In the 330 cases with skeletal metastasis (table A)

that I obtained from the literature 261 (79.9 per cent) were

-6-

Tabula.tion of ?tesult;:: of ~{oe11tgen-~19~y Ther~:Lpy in 330 Oases of
l1:etaGtatic CarCinOl::1a to Bon6, !~ppearing in the Li terc"ture
(78, 57, 56, 75, 73, 82, 33, 58, 5'.})

Results of Therapy on Symptoms

Primary
Carcinoma
No

Complete

Relief

Relief

Partial
Relief

Not
Known

Case

64

144

32

21

Perc en

24.5

55

12.5

8

23

7

27

11.3

43.5

Breast
Case
Prostate

Parcez iii 37.1
Case

Thyroid

Hypernephroma

Totals

<:;

'"

Percent

261
79.9
62

19

8.1

2

Percei

Total

2

100

0.6

Case

1

2

2

PerC6l'1

20

4CJ

40

~ase

87

154

.:'
v.L

28

Percen

26.2

4·6.9

18.5

8.5

5

1.5
330
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from primary lesions of the breast.
The second most common carcinoma which metastasizes tobonee
is probably that of the prostate.

Bumpus, quoted by (57), has

found i t in 30 per cent of his cases, while Kaufmann observed
metastases to bone in 16 of 22 cases.

On 330 cases with skele-

tal metastasis (table A) I found 62 (19 per cent) in which the
primary lesion was located in the prostate.
Metastases to bone from carcinoma of the thyroid, lung,
uterus and cervix, urinary tract, and gastro-intestinal tract
are no doubt decidedly less frequent.

Ginsburg (39) remarks:

uIn 1892 in a report of 50 ca.ses of carcinoma of the thyroid
at the Vienna Pathological Institute from

l882-l89~,

stoistner found metastases to bone in 20 per cent.

HinterIn 1902

Ehrhardt, at Kocher's Clinic, in 238 cases of thyroid tumor,
found skeletal metastases in 66. 1t

I found in 330 cases with

skeletal metastases (table A) that the primary lesion was located in the thyroid in only 2 cases (0.6 per cent) and in the
kidney in 5 cases (1.5 per cent).
The bones most frequently involved are the spine, pelvis,
femur, ribs, and humerus.
and pelvic metastases

Leddy and Desjardins (56) found spinal

by far more common.

Peden (53) believes

that metastasis below the knee or elbow are extremely rare.
Pfahler ('14) has found metastasis (in order of fre('~uency) from
breast to spine, pelvis, femur, skull, ribs, humerus, and
sternum; from prostate to pelvis, spine, and ribs; from thyroid

-8-

to spine and sternum; from hypernephroma to pelvis, spine, femur,
humerus, ribs, feet, skull, and sternum; and from ovary and
uterus to pelvis and spine.
As hEtS been emphasized by numerous writers, metastatic
carcinoma of bone is merely one manifestation of a generalized
carcinomatosis.

Therefore, in treating these lesions we cannot

hope for cures.

The best that can be expected is for amelioration

of symptoms and prolongation of life.
states:

(73, 12)

Pfahler (74)

"The local lesion can be cured with brilliant results,

however the generalized metastasis allows progress of the disease in other tissues or localities."
The success of irradiation in the treatment of secondary
carcinoma of bone depends primarly upon the sensitiveness of the
malignant cells to irradiation.

The metastatic cells from the

breast are generally accepted as being the most sensitive, while
those from the thyroid are second and from the prostate , third.
Metastasis from the urinary tract, uterus and cervix, and the
gastro-intestinal tract are distinctly the least sensitive.
(47, 54" 74). Herendeen (42) in speaking of secondary

from breast to bone st'3.tes:

carcinoma

"It may be said that in general

the response of these tumors as compared with the response of
other carcinomatous metastasis to bones, as indicated by relief
from pain and evidence of attempt at repair, is

mo~e

prompt

and indicates a sensitivity seldom demonstrated in carcinomatous metastasis from other glands. tt

He says also that prostatic

metastasis to bone respond to irradiation with only relief from

-9-

pain, while the response of similar lesions from primary tumors

of bladder, uterus, and gastro-intestinal tract is indeed disappointing.

In table A we find in 261 skeletal metastasis from

the breast that 55 percent obtained complete relief, 12.5 per
cent partial relief, 24.5 per c cnt no relief t and 8 per cent
results not known; in 62 cases from the prostate 11.3 per cent
complete relief, 43.5 per cent partial relief, 37.1 per cent
no relief and 8.1 per cent results not known; in 2 cases from
the thyroid both had complete relief; and in 5 cases from hypernephroma 1 had complete relief, 2 partial relief, and in 2 cases
the results were not known",
Lenz and Freid (58) in using roentgen rays and radium in
treating secondary carcinomatous lesions from the breast have
observed:

tlThey caused diminution and at times marked temporary

regression of the clinical and roentgenographic signs of skeletal metastasis.

Clinical improvement started 24 to 48 hours

after the first treatment and lasted a few weeks to years. tt
Roemer (82) says:

"The patients are made quite comfortable

and are able to perform their household duties, and life can be
prolonged for several years."

Peden (73) remarks:

"The patient

with bone metastasis from carcinoma of the breast may not by
x-ray therapy have her life prolonged, but she certainly is
relieved of suffering and made more comfortable than without
x-ray. It

Pfahler (5) concludes:

"Only local curative results

and a prolongation of life from one to four years can be expected.

The healing is indicated by a recalcification of the

-l()-

affected part.

Involvement of other parts of the body must be

cont:mually expected."
The opinions appearing in the literature are agreed that
irradiation of prostatic carcinomatous metastasis to the skeleton, though not as effective as with similar lesions from the
breast, is still definitely of value.

Leddy and Gianturco (57)

have observed that a beneficial effect from roentgen treatment
is obtained in about one-half the cases of pain from meta.stasis
in cases of carcinoma of the prostate gland.
Skeletal metastasi s from the thyroid gland respond in a
manner comparable to those of the breast when subjected to
irradiation.

(74, 32, and others)

In metastasis from other glands to bone it is generally
agreed that the results are quite disappointing.
(42):

Herendeen

"The hypernephroma appears to be one of the most resistant

to radiation of all carcinomatous metastasis to bones.

Thbse

tumoY'S are highly vascular and this may be a factor in their
radioresistance, It

He also claims that the skeletal metastasis

from primary carcinoma of the bladder, mouth, tongue, eye, and
cervix respond very poorly to irradiation with little if any
relief fro;n symptoms, thus suggesting radioresistance rather tha.'1
sensitivity.
Rose (83) in speaking of metastatic carcinoma to bone aptly
remarks:

"I have satisfied myself that, althou?h this treatment

does not cure, it prolongs life,relieves the sufferers of their
pain to a surprising extent and often :makes them able to enjoy

-ll-

life and participate in activities of their home or even their
business to such an extent that they feel the x-ray treatment has
put them back on their feet again. II
Irradiation accomplishes its results by distruction of the
carcinomatous cells.

These neoplastic cells are more sensitive

to roentgen rays than are the osteoblasts of the bone.

There-

fore, by giving such dosages of x-ray as will destroy the malignant cells and not the bone forming cells we can stop the progress of and even kill the former a..'1d thereby allow the latter
to repair the
remarks:

.-.

dfu~aged

bone.

(74, 75, 63, and 57)r Pfahler (75)

"If we had primary carcinoma of bone, our most brilliant

results would occur here; but the generalized carcinomatosis
is responsible for our failure in metastatic carcinoma to bone."
Dresser (33)

from 1929 to 1934 has treated 50 cases of

carcinoma of the breast with skeletal metastasis to bone by
irradiation of the ovaries.

His results were quite satisfactory

especially in those patients who had not yet reached the menopause.

He found in this group that 30 per cent obtained com-

plete symptomatic relief with bone regeneration which lasted
from several months to two to three years, and that 43 per cent
showed temporary symptomatic relief.

The results in the patients

who had passed the menopause were not so encouraging, 48 per
cent experiencing only slight relief.

His technique of ad-

ministration of irradiation consisted in:

"200 K. V., 50 cm.

distance, 0.5 rom. Cu filter, 600 tr' measured in air, and given

-12in front and back of pelvis respectively through a 15 cm. by
15 cm. portal.

This dosage will produce a cessation of menses

in tne average women 35 or older.

In younger or more obese

women the depth dose should be increased, preferably by increasing the skin distance from 50 cm. to 80 cm.
is gener"3.lly given in daily doses of 300

l

The treatment

r ' each.

Menses

should cease in two months."
In treating the skeletal metastasis it is much better to
use high than low voltage technique for as pointed out by
Pfahler (74) the over-lying tissues absorb less rays with high
than with low voltage., The usual procedure is to use from 200
to 240 K. V., 4-5 rna •• skin distance of 50 cm. to 80 cm •• filter
0.75 rom. eu plus 1 rom. Al and delivered

thro~gh

as many portals

of entry as available; to the pelvis four fields are recommended,
an anterior, posterior, and two lateral fields; and to tne
spines bilateral fields with the rays converging upon the spines.
Most authors use from 80 per cent to a full erythema skin dose
delivered at one setting or at daily intervals so regulated as
to obtain a full de:th dose which is to be maintained.
(74) suggests the following procedure:

Pfahler

"Deliver gradually an

erythema dose into affected (by daily doses) tissues within a
week to ten days, and then maintain saturation for ru10ther week
to ten days.

~fter

this a 50 per cent dose delivered into the

part in two doses at an interval of one month will probably give
best results."

(32,80, 56, 57,89,75,82).

The patient who has a primary carcinoma especially in the

-13breast, prostate and thyroid ShO,11d be carefully watched and
x-ray plates taken to determine whether there are skelet~l metastasis.

This is especially true where there is a history of pain

which is apparently located in the bones.

As has been emphasized

by various authors (SO, 12, 73, and others), the earlier roentgen
ray therapy is commenced in such skeletal lesions the more
striking will be the end results.
Malignant Invasion of Bone.
Tyler (92) presents three cases with malignant bone invasion which have apparently been greatly helf-ed through the
use of radiation therapy.
Case 1:

Male, age 41, with erosion of mandible from left

angle to incision region by a squamous cell carcinoma.

It was

treated by high frequency electrical current (coagulation of
diseased mandible) and heavily filtered radium.

Patient well

four years after treatment.
Case 2:

W~le,

age 45, with cancer of floor of mouth and

gums involving the mandible.

It was treated with

rad~um

and

high voltage x-ray using tolerance dosage over a period of
three months.

At the pre1sent time the mandible is completely

gone from first molar to last molar, but the floor of the mouth
is covered by normal closed mucous membrane and the tongue is
unchanged in shape.
Case 3:

There has been no recurrence in nine years.

Male, age 41, with a squamous cell carcinoma of

the inner left cheeck involving the left mandible, left floor
of mouth and left anteri-o.r pillar of pharynx.

Patient was treated
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by high frequency electrical current and removal of coagulated
tissue followed by heavily filtered radium.

At present time the

mandibular border is now depressed from the left angle to t.he
right cuspid.

The floor of the mouth and inner side of the

cheek are covered by normal mucosa.

The left side of the tongue

is fixed to the floor of the mouth with exception of 0.75 cm.
at the tip.

The patient can talk but has difficulty in forming

words involving the use of letters as p, t, and b.

The patient

is well with no evidence of recurrence for more than four years.
Larkin (55) in speaking of epitheliomata (of either the
basal or squamous cell type) says:

"Lesions in which the carti-

lage or bone are involved have not been cured or healed by us
without employing surgical measures.

Inrcibition of growth, pro-

longation of life, and promotion of comfort are accomplished,
but in no case has healing occurred from radiation alone. 1I

Of

his seven cases with bone and cartilage involvement and treated
by screened irradia.tion, 8.11 cases were living with the disease.
It appears that even with this inadequate number of cases

irradiation is definitely indicated as an adjuvant to surgical
procedures in the treatment of carcinomatou s lesions (especially
epitheliomata) which have invaded bone.
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PERIOSTEA.L FIBROSARCOMA.
These tumors are apparently exceedingly rare.

In the

literature I found reference specifically to only four cases
which were mentioned briefly by Coley (19).

Kolodney (52),

though he did not give percentages did emphasize the rarity
of ti"ese neoplasms.
The periosteal fibrosarcoma ari ses from the outer fs.sdcular layers of the periostiur:J and possibly the adjacent fascia
and tendinous insertions.

It does not invade the adjacent

cortex, but may by pressure erode the surface.

They contain

no osteoid tissue being composed principally, as the name implies,
of fibrous and sarcomatous tissues.

(52 and 34)

Moore (69) in

speaking of these neoplasms says that they are lesE distinctive
in their radiological manifestations than are the osteogenic
group.

He believes that their spread and metastasis are

apparently the same as sarcoma arising in the soft tissues and
wholly independeut of bone.
In treating these tumors

Pf·a.~ler

(74 and 75) recommends

the use of irradiation to be foll.owed probably by
In discussing therapy Coley (19) says:

an1 c:utation.

"The periosteal fib-

rosarcoma which is characterized by little bone involvement we
have found most responsive to treatment.

Three patients are

well three years and one is well two years.
alone in one and toxins and irraa'ia+'ion
concludes:

1"

We used irradiation

n t I,1'lree."

K0 loo.ney
'
(r2)
;)

•

"The periosteal fibrosarcoma of the cases registered

bear out the fact that this tumor is of decidedly better prognosis

-16-

than the osteogenic sarcoma.
From this one might assume that these tumors, though rare,
do have a much better prognostic outlook than ttl:; osteog<cnic
sarcoma.

Further, they are apparently relatively radiosensitive

and should thus be treated, no doubt, by the use of full
tolerance roentgen-ray thera.tJY followed possibly by surgical
removal or amputation.
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OSTEOGWNIC TUMORS

The term osteogenic as set forth bf the Registry was intended to apply to those tumors derived from the ancestors of
the mature bone cells, which are osteoblasta.

These cells,

however, may not be producing bone, for this is only a potential
characteristic.

Accordingly, the predominating cellular element

may be, dependL:g upon the degree of differentiation, mucoid,
cartilaginous, spindle cell, and so on, or a. combination of two
or more of the above.

The malignant charact er of the Ee tumors

may also be as varied as the cell type.

Some are definitely

benign while others are highly malignant.

Ranging between thSfl6

two extremes we find them shovv'ing varying degrees of benignus
and malignancy.

For practical purposes the group as a whole

may be divided into three main divisions:

(1) benign osteogenic

tumors, (2) borderline osteogenic tumors, and (3) malignant
osteogenic tumors (osteogenic sarcoma). (52)
The Benign osteogenic Tumors
This group includes the exostoses, osteomas, chondromas,
fibromas, myxomas, fibrochondromas, fibromyxochondromas, etc.
The class as a whole is composed of tumors which are benign
from the onset and tend to remain eo.

A.s long as the benign

character persists, they are non-sensitive to radiation.

Under

these circumstances treEttment is entirely a surgical problem.
(32, 2, ll, 47)

-
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The Borderline Group of osteogenic Tumors
Desjardins and Popp (32) and others have emphasized the
fb.Ct that under

cert~,in

circumstances, especially repeated

surgical treatment of recurrences, the benign osteogenic tumors
tend to undergo malignant degeneration.

This, as emphasized by

Evans and Leucutia (34) is especially true of the chondroma and
myxoma.

In speaking of the chondroma th6y say:

"They may remain

Quiescent for years until trauma suddenly produces a chs..nge for
the worse.

At this time the cartilaginous matrix becomes richer

in blood supply, the benign cell element gradually undergoes
malignant degeneration, and often distinctly sarcomatous changes
result.

The course from this moment on is not unlike that of

osteogenic sarcoma.
closing chapter. It

Generalized metastasis, as a rule, forms the
They further state that in treating this lesion

a sharp line must be drawn between the two stages.
remark:

liAs

They aptly

long as the process maintains its benign character

and remains localized to one focus, irradiation is of little
benefit and radical surgical intervention is the treatmeGt of
choice, but as soon as the lesion becomes generalized and signs
of malignant degeneration appear, irradiation, in the form of
deep x-ray becomes of great value.

This manifold behavior of the

chondroma to irradiation is easily explained by the histological
changes occurring within che tumor. Since cartilage is highly
resiste..nt to x-r8.y, the responSE to irradiation would be nil.
As

soon as the cartilage shows malignant degeneration, a typical

cell element will make it's a.t,pearance, and as these elements,

-19-

as a rule, are more or lese raciiosensitive, irradiation will
result in their destruction, wi--h ultimate clinical arrests of
the process, lasting for a period of many years."
Bloodgood (11) is of the opinion that there have been no
cases of myxoma which have been cured by surgery alone.

He

states that in all cases recurrences following surgical attack
have occurred within several months to a year.

,,;vans and Leu-

cutia (34) report one case of myxoma which they cured by the
use of curettage and cautery followed by a thorough course of
roentgen-ray therapy.
As long as these benign

-

osteoge~ic

tumors, the chondroma

am1 myxoma, maintain their non-malignant charact ;:;r, as evidenced
by clinical course and growth of the neoplasm, the treatment is
surgica~

However, as soon as the picture changes for the worse,

thB.t is, malignant degeneration occurs, then irradiation, in the
for,;, of deep x-ray therapy, becomes as sentiall.s an adjuvant to
surgery.
The Osteogenic Sarcoma (Malignant Osteogenic rumors)
Many attempts have been made to subdivide osteogenic
sarcoma by classifying them according to preponderance of cell
ty?e, i.e., spindle cell, giant cell, chondromatous, etc., or
anatomically as periosteal, subperiosteal, medullary, etc.
(69, 34, 52, 35, 14 and others)

HovJever, as pointed out by

Kolodney (52) such a classification has little, if any, clinical
significance for regardless of predominating cellular type or

-20of anatomics.l variation the::rognostic outlook and therapeutic
application is little diffsrent.

To attempt to use such a

terminology as is suggested above would only make the paper :nors
confusing.

This group in general will be spoken of, therefore, as

a whole rather than to use such subdivisions.
The osteogenic sarcomas are highly malignant.
observes;

Moore (69)

"Osteogenic Earcoma spreads rapidly into blood vessels

and spaces '/hieh may form. along' areolar tissues, and for
distances -which cannot be suspected. II

He also brings out the

fact that tpey tend to :netastasiz e early throug:-'l the blood st-ea;n.
Kolodney (52) point s out that these tumors not infrequent 1y
spread

Ul)

and down the medullary canal for considerable distances.

Barnes (1) remarks:

"Pulmonary and pleural metastasis occur y?ith

striking frequency in the bone malignancies, particularly in the
osteogenic group.1t

The individual who develops one of these

new-growths, therefore, has a definitely bad prognos-s.

Tumors

which grow rapidly, metastasize early, 3.s"1d are highly inv'3.,siv8
are difficult to control with any type of therapy.
It is generally conceded that of the primary malignant
bone tumors the osteogenic sSTcomata are decidedly the least
sensitive to irradiation.
poorly.

The group as a whole responds rather

There seems to be some difference of radiosensitivity

within the group it self, depending apparent 11 to some extent
upon the predominating :3e11;.11ar element.

Those tumors wr,ich

are made up largely of eartib.ginous tissue seem to be the
more sensitive, while the myxomatous ty}e seem to be most

-21-

resistant.

Another factor which appears to have some bearing

upon sensi ti vity is the anatomical location.

It h':is been observed

that the periosteal group are seemingly mors resistant than the
medullary group.

(1, 40, 2, 24, 88, 55, 13).

By the use of heavy thorough irradiation i t is possible in
most cases to obtain regression of the tumor and relief from
symptoms.
temporary.

However, the results are, except in rare instances, only
Sooner or later, in the majority of tDe cases, the

neoplasms again become active, and the final chapter consists of
metastasis and death. (43, 30).

It has been pointed out by

Bartlett (2) and others that apparently a large percentage of
reported cases are not true osteogenic sarcoma.

Bartlett (2)

has shown that in the accepted cases of the Registry the cases
well five or more years were predominately composed of chondromatous tissue and were, therefore, not true osteogenic sarcoma.
Desjardins (30) and Herendeen (43) as well as others have
separated the chondrosarcoma from the osteogenic group.
jardins has observed:

Des-

ftBy sufficient intense irradiation

chondrosarcoma can be made to retrogress perceptibly and sometimes to a consideraole degree for a limite!3- period of time
(weeks or months) but, as osteogenic sarcoma, complete and
permanent disappearance of such a neoplasm is a rare occurrence."
Bloodgood (8) states that prior to 1913 there were no verified cures of sarcoma of the long bones treated by amputation
or any other method.

In 191:5 two cases which he operated became

-22-

five year cures in 1918.

qe further points out that in 1920

less than four percent of the cases showed five year cures, and
in 1932 twenty-five percent.

He attribut.es thi s improved prog-

nostic outlook to earlier diagnosis resulting from education of
the public to the value of x-ray pictures with

pai~

swelling,

tenderness, loss of function, or injury to the skeletal
structure.

Barnes
(1)) aptly expresses it:
,

"At this time early

diagnosis is important, for.too many bone tumors are treated by
massage, bakes, high frequency current, baths, etc."
There is considerable dispute among various authors as
regards the method of treating these bone tumors.
three main types of therapy:

There are

(1) surgical intervention, (2)

irradiation of involved region, and (3) the systemic
toxin prepared by Coley.

use of a

Some years ago Coley observed a

spontaneous cure of a malignancy in a patient who developed
erysipelas.

Following this he worked out an erysipelas and

prodigiosus toxin which when injected subcutaneously has
apparently produced some rather striking results in his and
a few other hands. (20, 22, 21).

Besides the above three

forms of therafY we find all possible combinations of them
being used.
Neill (71), Moore (69), Evans and Leucutia (34), Palmer
(72), and others favor early radi-cal surgery and possibly
post-operative irradiation.

Opposed to this we find Brooks (13)

and others who feel that the radical renoval of tUmors by
surgery is haruly justifi8.ble, and. recommend the palliative use
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Tabulation of r-tesults of Therapy in 522 Cases of Osteogenic
Sarcoma Appearing in the Literature.
(68, 11, 24, 19, 17, 77, 70, 49, 2, 26, 92, 61, 86, 51, 4, 67, 28)
~ymptcfio

Years Patients Survived

No

matic

Therapy
Re-

~elief

Used

Per

sults

Only
Surgery
Alone

81.9

7

Percen '
Jase

Radiation Perc en

&,

'7

6

Alone

Radiation

13.9 16.2

6

13.9

6

13.9

2

6

6.9

4.6

13.9

13

7

61t5~

3.5

43

29

18

17

8

25.6

17.2

10.7

10.1

Gase

Percen,
Gase

3

~

Tota cent
22

3

13

45

3.5
43

8.2

20
3.8
158

1.7

32.1

16

20

44.4

55.6

1

9

•

Toxins Perc en

10

36

7
10

90

Surgery, Case
Radiation,
&,
Toxins. ere en

Totals

over

lS.1

Case

Toxins

4-5

Fercer.

Toxins

&,

3-4

18

Percen 16.2

Surgery

'·2-3

4

Alone

&,

l-2

Case

Radiation Case

Surgery

')-1

10

1.9

10

10

Case

20

6

51

35

24

53

ercen

3.8

1.1

9.8

6.7

4.8

10.1

5

115

9.7

22.2

1.9
309

60

Of the remaining 213 cases,all treated by surge1'Y' irradiation;
204 cases did not survive three years, one was well eight years but
not followed, and eight were not traced.
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of x-ray where it is possiblE; to m2tke the patient as comfortable
without subjecting him to the mutilating procedure of amputation.
Others who favor irradiation alone or as an adJuvant to surgery
are (11, 6,7,48,74,41, and numerous others).

Coley (17 to 23)

is the strongest advocate of the use of toxins and r6COfl.u11ends
their use in combination with surgery.

He states:

III believe

that an amputation as soon as diagnosis has been made, followed
by f;rolonged treatment with Coley I s toxin is the method of choice.
This method has given a higher percentage of
alon6, or amputation followed by radiation."
remark:

C~lres

than amputation

Pfahler and Parry

"Preliminary irradiation of tj:.e tumor area and irradiation

of the pulmonary area followed by amputatio., has given us the
best results to date, but based upon Hofelder's results i t wou':'d
seem that we have not waited long enough for the full beneficial
effect of the irradiation. I'

Bloodgood (9) has aptly concluded:

"The treatment will depend upon the point of view of the one
responsible, the choice being between x-ray or ra().ium radiation
and exploration, with further diagnosis by gross frozen sections,
followed by resection or am:Jutatiou. II
In the 522 cases of osteogenic sarcoma which I found in the
literature (table:s) surgery alone was the method of choice in
22 cases (3.5 percent), radiation alone in 43 cases (8.2 percent),

toxins alone in 20 cases (3.8 percent), surgery and radiation in
381 cases (73.1 percent), surgery and toxins in 36 cases (7 per
cent,), radiation and toxins in 10 cases (1.9 percent), and surgery,
radiation and toxins in 1::1 cases (1.9 percent).

SurEe:ty alone or
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supplemented by some other method of therapy was used in a total
of 449 cases (86 percent).

The cases which recieved toxins as

a supplement to surgery were largely those treated by Coley (17
to 23).

Irradiation was used as a

39l(a7 percent) of the 449 cases.

sup~lement

to surgery in

If this data has any signi-

ficance, we cannot. help but conclude that surgery with irradiation
is the method of choice.
The percentages of cures and relief from symptoms as set
forth in table B are not very reliable when considering the
group of osteogenic sarcoma as a whole, for the 522 cases
represented there are largely those cases in which the
of therapy have been more or less satisfactory.
authors do not report their

unsatisfac~ory

resu~ts

As a rule,

results.

There are two schools of thought with regard to the use of
irradiation as a supplement to

surger~.

In ODe school, Herendeen

(42) and others, preoperative irradiation is advocated.

The opinion

here is that irradiation so used brings about a retrogression of
the tumor grovrth and tends to lind t it by encapsulation.

Besides

irradiating the tumor area they also feel that the lutlg fields,
the most common site of metastasis, shou.ld, even though apparently
negative radiographically, be irradiated.

Such pre0i-:erative

irradiation of the lung fields may destroy small foci which later
on would be much more difficult to control.
Simmons (88),

K~err

Meyerding (66),

(50) and others are opposed to preoperative

irradiation, for they feel that the added delay only enhances
the possibilities of metastasis and for this reason feel that
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early diagnosis,

promp~

radical surgery and heavy thorough

post-operative irradiation are the method of choice.
It seems to the author that the logical thing to do is to
start some form of therapy whether it be toxins, irradiation or
surgery as soon as a diagnosis of a possible bone tumor is made.
Ndturally if there is any question as to the character of th"
neoplasm the more conservative procec.ure should be followed.
However, every attempt shot.l.ld be made to arrive at an early exact
diagnosis.

ijlfnen this early diagnosis is that of osteogenic sar-

coma imm.ediate radical surgery followed by a thorough course of
irradiation of tumor area and lung fields appears to be the
most sensible course.
In those far advanced cases of osteogenic sarcoma not amenable to surgical attack because of the extent of the new-growth,
irradiation as has been pointed out.by Simmons(88), Moore (69},
Coley (19) and others is of definite va.lue as a palliative
measure to make the remaining weeks or months of the pstientts
life more endurable.
In using irradiation thera)y for the treatment of osteogenic sarcoma one can use either radium or high voltage x-ray.
However, because of the expensiveness of the former and the large
quantities needed few have been able to use it.

Coley (22) has

used it in a number of cases and recommends the following:
"Radium pack containing large doses--2,OOO millicuries of
5 hours, Le., a total of 9,000 to 10,000 millicuries at a

4-~-

to
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distance of 6 cm. or from 12,000 to 20,000 mi1licuries applied
at a distance of 10 cm.

In the lonE bone cases the treaim6nt is

given over three aspects so that the total dosage often reaches
as high as 30,000 to 60,000 millicuries."
High voltage x-ray, because of

av~:dlabili ty

',.nd tha-;:; it is

equally as satisfactory as radium, is more commonly used.

Rapid

saturation to the:,oint of tolerance with subseQuent mai!'ltemmce
doses is gener o .lly recommended.
with these tumors

Ifie

As pointed out by Desjardins (29)

must take drs-siie steps and have less regard

for surroundi ~g soft tissue siructures if we are to attain the
best result s.
1

lIlill.

It is usual to use from 20J K. V. to 220 K. V., a

to 2 rum. eu filt8r, 45 cm. to 50 em. skin distance, and

the radiation being given through as many ;orta1s of entry as are
availablo.

The fracti.onal. method is to be used with doses being

given once and even twice daily.

(49, 54, 29, 74, ,md others).
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INFLli.!\4Mi"_TORY CON!)ITIONS
These are mentioned here only because of the fact that they
are important from "the standpoil1t of differential diagnosis.
Inflammatory conditions such as osteitis fibrosa cystica, myositis
ossificans, osteoperiostitis (traumatic, syphilitic and infectious),
simple bone cysts, and Paget· s disease !!lay clinica.lly similate a
bone neol)lasm and must oe differentiated from them before therajJy
can be instituted.

(34:, 49, 52, 15, 2, 8...Y!d oti'l.ers.)

Marland (62) has also em)hasized the fact that malignant
sarcomatous degeneration has, especially in Von Recklinghausen's
di se:U:;8 and Paget· s di sease, rarely oc curred.

Under such

circumstances irradia.tion, as in other osteogenic sarcoma, would
be indicated.
Merritt

(64), Pohle and Paul (81), Costlow (26), and others

reported cures in osteitis fibrosa cystica fallowing the use of
roentgen-ray thera 12Y of the involved area..

Merritt's cases were

treated by x-ray therapy of the par thyroid and they showed good
results.
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The term Benign Giant C;ell Tumor has been accepted by the
Registry to represent this group formerly called
Sarcoma.

There is

SO ',6

Gi&~t

Cell

conflict of opinion in the literature

as to whether these tumors are benign or maligna.t'l'u.

Goforth

(40) believes that i t depends upon the predominating cell type.
5e points out that some of the tumors contain a high percentage
of mature adult cells while others are compo.sed largely of
immature more active young cell elements.

The former, he believes,

are always benign, while the latter may show tendenciEls to become
malignant.

This tendency to malignant degeneration is pointed

out by other authors. (87, 60, 93, 16,47, and others).
\35

a.~d

Ewing

37) and stone and Ewing (91) have pointed out the fact

that malignant degeneration usually occurs following repeated
surgical attack for recurrences.

Ewing is of the opinion that

the tumors are essentially benign, but that by repeated
irritation and traUt"na the cellular elements might undergo maligna.~t

degeneration.

This follows Kolodney's theory- of trauma

(see etiology of bone tumors page 4) and is also emphasized by
oti1er<;; who feel the tumors are esseutially benign (65, 90, 14,
and others).

I axn inclined, from my reading, to agree with the

latter viewpoint.
The benign giant cell tumors respond to irradiation in a
manner which is characteristic of none of the other bone tumors.
Shortly after being exposed to roentgen-rays these tumors respond
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with marked swelling and incre3-sed pain, tenderness and redness
which often leads the novice to feel that the condition is becoming worse.

This has in certain circumstances been the factor

back of unnecessary amputation.

Apparently the larger the dose

of roentgen-rays the more marked is this reaction.
(42 a..YJ.d 43) and
carefully

Pfa..~ler

re~ulated

Herendeen

(74) state that by the use of small

dosages of radiation they have been able to

avoid this soft tissue reation in all of their cases.

However,

if the use of irradiation is properly continued, in four to six
weeks the reaction gradually subsides with a correslJonding
disappearance of symptoms and dsfini ts growth restraint.
Ossification can then be demonstrated by x-ray and progresses
to complete dense." calcification of the whole tumor mass.

In

these neoplasms the age of the patient is a definite factor
with respect to response, for the younger the patient the more
sensitive are these new-growths.

As compared with bone neoplasms

as a whole, the benign giant cell tumor is less sensitive to
irradiation than the endothelioma of Ewing or the multiple myeloma and more sensitive than the chondrosarcoma of the osteogenic group.

(37, 74, 54, 46, 76, 42, 43, and others).

Again, as in the osteogenic group, there is considerable
disagreement as to vi"hich method of therapy is to be used.
Radiation has been favored by some, curettage and cautery by
others and toxins by still

other~

Pfahler (76) was apparently the first individual to treat
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the benign giant cell tumors witt irraciiation.
started treatment of a case which was
still well in 1932.

rG~orted

In 1906 he
in 1907 and was

As pointed out by Coley (18), Herendeen (',2),

through his work has. proved definitely that giant cell tumors
can be cured by radiation.

Coley, however, feels that, as yet,

there have not been sufficient csses, so treated, to determine
whether irradiation or curettage is the better method.

He also

feels that the patient treated by irradiation is subjected to a
longer period of disability and thus an added expense as compared
to the patient treated surgically.
not agree with this.

He states:

Herendeen (45 and 46) does
riA more rapid ossification is

brought abol.-itwith a more rapid restoration of function than
when surgical procedure is the method of choice."

He points out

that by the use of a walking Thomas splint he is able to keep his
patients ambulatory and thus there has been no real period of
disability from the time tre9.tments were started.
Another argument Goley presents is that without biopsy one
is unable to determine whether the tumor is benign or malignant.
However, as has previously been stated, those cases showing
malignant degeneration are more frequently those which have had
repeated surgical attac;{.

Furthermore, Herendeen (30) states

that the roentgenograph can usually be relied upon to establish
the diagnosis, and, Pfahler and Parry (76) are of the opinion
that if an expert radiologist is in doubt, so, also, will be
the pathologist.
In favor of roentgen-ray therapy Herendeen

(4~))

further

______""_____________--....,...-_m______--___

~,'
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points out th-;;t reeurrences occur in about 25 percent of those
cases subjected to surgery, that the proba -ility of infection is
increasediiby surgery, that because of infection or recurrences
amputation may be necessary, and that the functional results
following surgery are frequently unsatisfactory because of varyirgdegrees of ankylosis.

Pfahler and Parry (76) agree with this

and further add that by breaking through the well encapsulated
tumor in doing the surgery one prepares, by setting free cells
and fragments of tissue, the way for metastasis.
Herendeen, Pfahler and Parry and others have pointed out that
x-ray therapy when used following surgery is less effective than
if surgery has been used.

For this reason they feel that x-ray

is deserving of a fair trial before surgery is used.
Again Coley (18) is the advocate of the use of toxins which
in his hands have produced some apparently satisfactory results.
He remarks:

!tIt is possible to cure benign giant cell sarcoma

and even far advanced borderline cases (giant and spindle cell
sarcoma) by the injecting of the mixed toxins of erysipelas and
prodigiosus without ot.her treatment.

Furthermore it is possible

to cure those cases by a comoination of toxins and radiation or
toxins and curettage."
Bartlett (51) is convinced:

~Je

know now that giant cell

tumor is curable probably in all instances by x-ray or radium.
These agents, whil( they may not cause any appreciable shrinkage
in the size of the tumor mass, do bring about an ossification
and limit the further spre9.c of the disease."

Moore (69) feels
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TA3LE C
Tabuhdion of Results of Therapy in 114 Cases of Benign Giant Cell Tumor
Appearing in the, Li teratur'e.

(11, 18, 76, 49, 79)

Years Patients Survived
Therapy

No

Symp
toma-

tic
Used

Surgery

ResuItsti.elief 0-1

Ca.se

...

PtTCen

5.5

Case

2

1

1-2

7

2-3

3

3-4

4-5

3

Toxin
Alone

-

':) a

16.6

Percen 33.3

A.lone
Percen

3

4

13 .3

10

13.3

Ca~5e

Perce.

1

1

2.5

1

1

8.3

8.3

1

2.5

9

22.5

Radiation, Case
Toxin &
Surgery

5

1

Totals
Perce f' 4.4 J.87

6

1

15

2.5

1

1

14.2

14.2

14

11

19.3 12.'3

9.8

Perce

Case

6

3

3

10

Inv

13

5.2
30

43.3

26.2
1

100

Perce ,,8.3
Case

Surgery &.
Radiation

16

33.3

1

'E'rCGYl .

Case
Surgery
&. Toxin

2

16&6

4

Radiation

Toxin

1

16.6

Radiation Jase

&;

22.2

1

21

Fercent

IS

4

Alone
0.J

overS Total

0.87

1
8.3

1

8.3

7

12

58.3

4

2

16

10

5

40
5

10.5

40
35

7

4.S

71.4

9

6

47

'1.9

5.2

41.2

114
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that radiation should. be the first method of choice.

SinliJJOnS

(88) is of the opinion that irradia-tion should be tried first, for
as he states:

"If it is unsuccessful, arnputation or operation

can follow later."

Desjardins and Popp (32) also advocate irra-

diation as do others (79, 59 and 38).
An analysis of table C will show that of the 114 cases
rei)resented there those treated by radiation received as good,
if not better, results than by any of the other methods.

Of

all the cases which received irradiation alone or supplemented
by some other form of therapy (78 cases) only one case whicH
also received surgery was not benefited, while in those cases
not receiving radiation (36 cases) four were not helped by the
therapy.

Thi s together with the other fact s shoITm in the table

as well as the discussion vibich has gone before point definitely
to irradiation as the method of choice in the treatment of the
benign giant cell tumor.
In treating these neoplams by the use of roentgen-ray
radiation moderate dosages are recomraended.
states:

Herendeen (42)

tlNot only may heavy doses be follovied by 'Severe,

unnecessary reactions or pathological fractures, but,
iml,ortant, bone regeneration may be retarded."
aptly concludes:

mor~

Desjardins (29)

",Giant cell tumors require only small doses

of rays of medium wave length.

It is easy t.o over treat such a

tumor and receive inferior results; whereas, if not over
treated, excellent results may be obtained. II

others are of

.~
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the same opinion

(~)4,

66, 76, and others).

Herendeen recommends the following technique:

"140 K. V.,

4 rna., 4 mm. Al filter, a 10-12 inch target skin dist8.nce, and,
dej)ending on the case, 6 to 12 minute exposure.

We have given

on the average of from 8-10 treatments, a serie::;. consists of
three exposures through different portals.

An interval of six

weeks to two montns is allowed to elapse before these treatments
are repeated. It

Other men agree in genera.l with this though

most of them have used a somewhat higher voltage, (200 K. V.).
(54, 32, 74, 47 and others).
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As pointed out by Kolodney (52) the angiomata of bone are
exceedingly rare.

Codman (14) has also emphasized the fact that

these tumors are seldom, if ever, seen.
of the angiomata says:

Kolodney in speaking

liThe term angiosarcoma given by Kolerzek,

originally was intended for the so-called peritheliomata, tumors
originating from the vessel wall and not from the endothelial
lining of the vessels.

Later this term found its way to tUmors

with a clear endothelial origin, which are better called angioendothelioma. II

Kolodney, because of the rarity of these heman-

giomas in bone, feels that they are not well enough understood
to justify a separate headin.g and has, therefore, placed them
under the heading of "Unclassified Tumors."

To this group he

has also added the periosteal fibrosarcoma which, he feels also,
because of their rarity, do not deserve a

separf~te

These hemangiomas consist of two groups, those
and those which are malignant.

heading.

wh~ch

are benign

(14, 52, 77, 74, and others).

Hemangiomata of bone arE> apparently moderately radiosensitive,
and react to irradiation as d.o similar neoplasms of other tissues.
Occasionally certain of these tumors show a mixed cellular element
of angioma and endothelioma character.

Under this circumstance

the resultant tumor is less sensitive to radiation than would be
a tumor composed wholly of either.
Popp (32) observe:

(32 and 66).

Desjardins and

ttRepeated irradiation is often, if not usually,

fol10"'led by gradual regression and improvement until healing
occurs.

Repeated and continued doses of 75 pbrcent to 80 percent

-37-

erythema dose repeated every three to four weeks

8.S

long as the

patient's condition continues to improve are recommended.
tumors oisappear relatively slowly.

The

Failure is due usually to

a failure to recognize the tumor, because treatment is not
repeated or continued long enough, or because excessive doses
are employed."
Pfahler and Parry (77), Kolodney (52), and others recommend
that the benign type of hemangiomc-, be treated by surgical removal,
while thE:; malignant angioma of bone, they feel, is best treated
by irradiation.
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Keating (49) stqtes tna+, these ne;N-grov.rths are one-fourth
as common as the osteogenic sarcoma (the largest group of the
pr~mary

bone tumors).

;.8 qointed out by Cofield (15) the neo-

?lastic cells originate from the endothelium of the blood vessels
and lymph channels.

The lesion is localized at the start to

one of the long bones, though it Glsually occupies the entire
shaft.

It is distinctly invasive of surrounding soft tissue

and apparently always eives rise tJ metastasis, but neither
is quite as marked as with the osteogenic sarcoma.

From the

start the disease similates, by its clinicalf)icture, (rarely
occuring after 20, temperature, leucocytosis, and pain) osteomyelitis and offers an interesting diagnostic problem because
of this.

(14, 53, 25, 35, 52, and others).

~{ingts

Tumor responds so characteristically to roentgen

or radium-rays that as brought out by Desjardins and POP9 (32),
Kress (54) and others, it is almost diagnostic.

The local

lesion, when exposed to irradiation yields in a very short

..L ' .

,,~me

with disappearance of symptoms, rvirogression of tumor mass,
and shortly later beginning ossification which progresses to
complete calcification.

If this local lesion were the whole

picture, the use of x-ray therapy would produce
results.

0 T

:nost brilliant

However, metastases almost invariably take place through

apparently both the lymph channels and blood vessels.

These

metastases, principally to the lungs and other bones but also
other tissues, apPElari thin a montIl to several years.

They
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respond to radiation therapy aL'llost as readily as do the pri;nary
t~,e

lesions, butoy this time

disease is so generalized that

only temporary amelioration of sy;nptoms can be hoped for even
with therapy carried to the very limits of tolerance.

The final

chapter is thus, almost invariably, death from the metastatic
lesions.

(88, 11, 54, 42, 31, 84, and others).

In the treatment of these new-growths we again find the
therapeutic application of radiation, surgery, toxins, and
combinations of the three.

Moore (69) feels that there is definite

indication that the disease may be systemic in character and
feels that for this reason radiation, in view of the sensitivity
of Ewing's Tumor, is the method of choice.
.~.

Some writers believe

that the almost invariable occurrence of metastases makes
radiation the only logical therapeutic step.

(1, 74, 53, and others)

Others, particularly Evans and Leucutia (34) are convinced
that the disease when it is just developing is a localized rather
than a systemic disease.

For this reason these authors advocate

early amputation followed by an extensive course of radiation.
Conner (25) concludes:

"The prognosis with a combination of

surgery and irradiation, is not always death.

Patients have

lived for five years or longer, one sixteen years, after amputation, and many who have been treated by a combination of
surgery, radia'ion, and toxins, are living over three yeA.rs after
the onset.

The prognosis seems to "oe distinctly bett er than that

of osteogenic sarcoma and other myelomata, and for this reason
it is urged that these

bf;

Gonsidered special cases ,in which, by

-40TABL"[ D
Tabulation of -::tesult s of 'f'her'JPY i:'l ?22 Cases of i-i;wi'1g's Sareoina
Appe8.ring in the Liter9_ture.

(16, 61, 25, 78, 74, 27, 31, 49)

Years P3"tient Survived
Therapy

Syrnp-

Used

tomatic
Relie

0-1

8

6

Gase
Surgery

-

Alone

Pe!"cen

Radiation
A.lone

Case

Perc en

40

1-2

2-3

6

22.8 28.2

4

IS.8

4-5 over 5 Tota] iPercent

30

c::
J

3-4
2

4

10

20

2

1

2

1

9.4

4.7

9.4

4.7

Toxin
dlone

Percer:

Surgery

Case

8.6

21
9
8

8

Case

20

3.4

100

12

8:;

Radiation ipercerJ; 42

5

2

1

2

1

17.5

'7

3.5

7

3.5
1

'~8,.se

5

28
12

17.5
8

9

Surgery
&.

1l.1

Perce!

3.8

88.9

'T'oxin
Radiation Gase

8

1

9

R·
w

Toxin

ipercer

Case
Surgery
Toxin 8c
Radiation Perce!

Case

1
~l2.5

27

3

8

2

2

3.4

2.5

37.5

2.5

20

8

3

'7

4

34

3.6

3.4

1.3

3

1.7

14.2

Totals
Percer ~1l.6

3.8

89.9

118

103

Of the rem>:H"1lng 129 cases: 128 were listed only as 8UrV,1.Vlng
less ~han 5 years of '\I\fhich 20 were tre3-ied by surgery '?,lone, 55 by itra.di;'ltion alone, '3 by toxi':'! 910ne, Ii] by surgery 'tl1d irreLdiation 8 by surgery 'lnd toxin, and 32 by toxin an:l radi:~tion. In the r:maining C'1se no
treatlnent was gi ,ren" T'-- e
. t
.
~
Il
::.en survlved only a short time.
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energetic measures, a permanent care may be possible."
Coley

(37)

(22) again is the strongest advocate for the use of

toxins, but in this disease he also em.phasizes ih", value of
irradiation.

He states:

"The method of choice is local irn'J.-

diation combil1ed with the systemic action of mixed toxins, reserving amputation for only those cases such as failed to show
markee, improvement under thi s treatment. tt
observes:

Meyerding (66)

"Early radio-therapy before metastasis has occurred,

may result in permanent curs.

Opinions as to the merits of

treatment recently appears to favor amputation, irradiation,
and toxins."
Table D which represents 232 cases of Ewing's TUmor which
were collected from the litera+.ure agree;;; fairly well w·ith the
opinions set forth above.

Of the 232 cases 40

(i7.2 percent)

were treated by surgery alone and only four cases survived the
five year period, 76 (32.7 percent) recieved irradiation alone
and only one case survived the five year period, 11 (4.7 percent)
recieved toxin alone and of these ei".ht were reported as
surviving the five year period, 38 (16.3 percent) recieved
surgery and irradiation and five cases were credited as surviving
the five year period, 17 (7.2 percent) recieved surgery and toxin
and eight of these survived the five ye8r period, 41 (17.6 percent) recieved radiation and toxins and· eight survived the five
years, 8 (3.4- percent) treated by surgery, toxins, ana irradiation
showed none who survived the five years.

The ceses treated with

toxins seem to show a higher perCEntage of five year cures.
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However, it must be remeLloered that these cases were largely
treated by Coley (16) and further the total cases recieving
toxin alone or with some other form of therapy were only 77
or 33.1 percent of the total 232 cases.

Only eight of the

77 were treated by toxins alone.
In giving the roentgen-ray irradiation the high voltage
technic (same as suggested for osteogenic sarcoma), delivered
through as many portals of entry as are availaba:e, and with the
rays converging upon the center of the turnor, is the usual procedure.

The patient should recieve radiation to point of tolerance,

and over a long period of time.
Desjardins and Popp (32) suggest:

(61,

42, 74_ and others).

ItSuccess of the treatment

depend.s upon a large total dosage concentration u;)on the tumor.
This may be accomplif.,hed by (1) cross firing using multiple
ports 'iii th careful calculation so that the maximum intensity of
irradiation is at center of the tumor.

:!!:ach field. may be exposed

to a moderate erythema dose on successive days (500 to 55J 'r'
measured in air) or small doses to all fields for from fifteen to
twenty days.

Important in using severs,l fields that the beellls

of rays converge on center of

t~or,

and as fields increase in

number respective doses to each fit ld must be decreased to avoid
tissue destruction from over radia ion.

If the initial course

is given. in vne week to ten days, it should be repeated t·wo or
three times at intervals of three to six or eight vieeks depending on

c~uality

of rays employed, numoer of ports, response of

tumor and condition of pati6n".

If treatment is given in small
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daily increment s continued. for twenty to forty days, or when the
total dose of rays directed towards the tumor is large, do not
repeat treatment or wait

t1)'lO

to six months."
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The multiple myeloma according to EVans and Leucutia ('A)
are very rare.

They have observed only one case, and point out

that only nine typical and five atypical cases appear in the
Registry over a period of five years ( 1923-1928).
The disease is characterized by the simultaneous appearance
of nodules of varying size in the marrow cavity of both the long
and flat bones.

The neoplastic cells are derived from the mye-

locytic series and may, therefore, be myelocytes, lymphocytes, or
erythrocytes.

The disease is generalized from the onset and tends

to develop insidiously, so that by the time it is recognized
it is most commonly far advanced.

The disease tends to metastasize

to the regional and more distant lym:ph glands and is also di6tinctly invasive of surrounding tissue.

(52,15, and others\.

The cells of the myelocytic series are quite sensitive to
roentgen and radium rays and therefore, respond readily to
radiation therapy.

The myelomata are generally considered as

being slightly less sensitive than the endothelioma of E'Ning
and more sensitive than the benign giant cell tumor.

However,

because of the genera.lized involvement from the onset and also
the insidious develo ~:ment, the disease can be only temporarly
controlled by the use of radation theral"Y'
ch8.racter of the disease is
surgery.
I

8.

1'he disseminated

definite contraindication to

Mixed toxins would appear to be of some value, though

found no mention of their

47, 66, and 34).

\l

se in the Ii terature.

1, 74,
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The prognosis is c3efinii:.
radiation t:nerapy states:

bad.

Pfahler (74) in discussing

!lDarboie and "iavigneow reported a

case in which temporary healing has lasted sixteen months, and
Regaua re)orted eight cases, on8 of which had local healing for

twenty-one months, but all died of the generalized disease in
the osseous system."

In treating this disease it is generally customary to use
the high voltage technic as suggested under metastatic carcinoma
to bone.

(32,74, and others).
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CONGEJSIONS
1.

IrradiEtt.ion ther8.PyLs of definite value in metast"ltic

carcinoma of bone, primary in other tissaes,
measure for amelioration of symptoms

~md

?,s

a palliative

prolonga" ion of life

from one to four or five years.
Irradiation therapy is indicated as an adjuvant to surgery
in malignant invasion of bone (especially with epitheliomata).
2.

In the treatment of periosteal fibrosarcoms" irradiation

is useful in conjunction with surgery.
3.

The benign osteogenic tu.lllors are radioresist8"nt and

shoClLioe treated by surgery.
The borderline group of osteogenic t ..imOrs are relatively
radiosensi ti V6 and should recieve irradhttion together with
surgery.
The malignant osteogenic tumors (osteogenic s'c<rcoma) should
recieve surgery and irradiation therapy and probably thEi mixed
toxins of Coley.
4.

Paget's disease and von Rechlinghausen's dis6'O'cse have

been cured by the use of roentgen-ray therapy.
5.

Irradiation thera)y is the method:;f choice in the

treatment of the bbnign giant cell tUlYlor s.

6.

The benign hemangioma are relatively radioresistant and

are, therefore, a surgical problem.
The malign'3.n-t hem:;ngiom':l should recieve roentgen-ray ther':Jpy
and surgery.

-47-

7.
~nd

~wingt

s Tumor (endothelioma) is very sensitive to x-ray

apparently responde to Coley's toxin.

The treatment of

choice is irradiation and possibly to;dns to be followed if
necessary by surgery (cures are rare).

8.

Irradiation therapy is useful as a palliative measure

in producing defini ts ai11elioration of symptoms and s..Lightly increasing life of p'1tients -who have multiple myeloma.
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